WILMINGTON, Del. — Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed...
Latest News
WILMINGTON, Del. – Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca’s SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The safety...
Cambridge, England – AstraZeneca on Monday released high-level results from the Phase III LAURA study, demonstrating clinical benefit for Tagrisso (osimertinib) as a maintenance treatment for patients with unresectable, stage III, EGFR-mutated non-small cell lung cancer. The pharma did not reveal specific data in its announcement but said that Tagrisso...
BOSTON, Mass. — Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Initial results demonstrate...
BOSTON, Mass. — Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart in people living with hereditary angioedema (HAE). “The initiation of ORBIT-EXPANSE marks exciting progress in the development of...
AUSTIN, Texas — Natera, Inc., a global leader in cell-free DNA testing, presented new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium (ASCO GI), that took place January 18 – 20, 2024 in San Francisco,...
STOCKHOLM — Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced data presentations highlighting additional analyses from the Phase 3 NefIgArd study with Nefecon in adults with primary IgA nephropathy (IgAN), as well as pre-clinical data on the treatment of Alport syndrome with setanaxib, a novel NOX inhibitor,...
EVRY, France — Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at the MDA (Muscular Dystrophy Association) Conference 2026 the first safety, pharmacodynamics, and efficacy results for its ATA-200 gene therapy in LGMD-2C/R5 limb-girdle muscular dystrophy associated with γ-sarcoglycan deficiency (SGCG, gamma-sarcoglycanopathy). The...
Evry, France – Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at the ASGCT (American Society of Gene and Cell Therapy) Annual meeting 2026the first safety, pharmacodynamics, and efficacy results for its ATA-200 gene therapy in LGMD-2C/R5 limb-girdle muscular...
THOUSAND OAKS, Calif. — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food...